Authors: Reindollar, R

Citation: R. Reindollar, Developing therapeutic plans for patients with chronic hepatitis B or C - A practical approach, CLIN GAS, 2002, pp. 189-209

Authors: Reddy, KR Wright, TL Pockros, PJ Shiffman, M Everson, G Reindollar, R Fried, MW Purdum, PP Jensen, D Smith, C Lee, WM Boyer, TD Lin, A Pedder, S DePamphilis, J

Citation: Kr. Reddy et al., Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared withinterferon alpha-2a in noncirrhotic patients with chronic hepatitis C, HEPATOLOGY, 33(2), 2001, pp. 433-438

Authors: Manns, MP McHutchinson, JG Gordon, SC Rustgi, VK Shiffman, M Reindollar, R Goodman, ZD Koury, K Ling, MH Albrecht, JK

Citation: Mp. Manns et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plusribavirin for initial treatment of chronic hepatitis C: a randomised trial, LANCET, 358(9286), 2001, pp. 958-965

Authors: Heathcote, EJ Shiffman, ML Cooksley, WGE Dusheiko, GM Lee, SS Balart, L Reindollar, R Reddy, RK Wright, TL Lin, A Hoffman, J De Pamphilis, J

Citation: Ej. Heathcote et al., Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis, N ENG J MED, 343(23), 2000, pp. 1673-1680